Patents by Inventor Hisashi Shinkai
Hisashi Shinkai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230190730Abstract: An anti-HIV agent containing, as an active ingredient, ex, 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.Type: ApplicationFiled: May 13, 2022Publication date: June 22, 2023Applicant: Japan Tobacco Inc.Inventors: Motohide Satoh, Hiroshi Kawakami, Yoshiharu Itoh, Hisashi Shinkai, Takahisa Motomura, Hisateru Aramaki, Yuji Matsuzaki, Wataru Watanabe, Shuichi Wamaki
-
Publication number: 20200308109Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.Type: ApplicationFiled: October 31, 2019Publication date: October 1, 2020Inventors: Takahisa Motomura, Hironobu NAGAMORI, Koichi SUZAWA, Hirotsugu ITO, Toru MORITA, Satoru KOBAYASHI, Hisashi SHINKAI
-
Publication number: 20200101061Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.Type: ApplicationFiled: May 10, 2019Publication date: April 2, 2020Applicant: Japan Tobacco Inc.Inventors: Motohide Satoh, Hiroshi Kawakami, Yoshiharu Itoh, Hisashi Shinkai, Takahisa Motomura, Hisateru Aramaki, Yuji Matsuzaki, Wataru Watanabe, Shuichi Wamaki
-
Publication number: 20190177271Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.Type: ApplicationFiled: July 23, 2018Publication date: June 13, 2019Inventors: Takahisa MOTOMURA, Hironobu NAGAMORI, Koichi SUZAWA, Hirotsugu ITO, Toru MORITA, Satoru KOBAYASHI, Hisashi SHINKAI
-
Publication number: 20150329491Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.Type: ApplicationFiled: September 12, 2014Publication date: November 19, 2015Inventors: Takahisa MOTOMURA, Hironobu NAGAMORI, Koichi SUZAWA, Hirotsugu ITO, Toru MORITA, Satoru KOBAYASHI, Hisashi SHINKAI
-
Publication number: 20150174117Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.Type: ApplicationFiled: June 10, 2014Publication date: June 25, 2015Inventors: Motohide SATOH, Hiroshi Kawakami, Yoshiharu Itoh, Hisashi Shinkai, Takahisa Motomura, Hisateru Aramaki, Yuji Matsuzaki, Wataru Watanabe, Shuichi Wamaki
-
Patent number: 9000045Abstract: The invention provides a compound that is a CETP activity inhibitor. The compound can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity. the invention also provides for the use of the compound to prevent or treat atherosclerosis or hyperlipidemia.Type: GrantFiled: March 21, 2012Date of Patent: April 7, 2015Assignee: Japan Tobacco Inc.Inventors: Hisashi Shinkai, Kimiya Maeda, Hiroshi Okamoto
-
Patent number: 8871934Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.Type: GrantFiled: November 5, 2012Date of Patent: October 28, 2014Assignee: Japan Tobacco Inc.Inventors: Takahisa Motomura, Hironobu Nagamori, Koichi Suzawa, Hirotsugu Ito, Toru Morita, Satoru Kobayashi, Hisashi Shinkai
-
Publication number: 20130172344Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.Type: ApplicationFiled: June 20, 2012Publication date: July 4, 2013Inventors: Motohide SATOH, Hiroshi Kawakami, Yoshiharu Itoh, Hisashi Shinkai, Takahisa Motomura, Hisateru Aramaki, Yuji Matsuzaki, Wataru Watanabe, Shuichi Wamaki
-
Publication number: 20130053417Abstract: The invention provides a compound that is a CETP activity inhibitor. The compound can increase HDL and at the same time decrease LDL through selective inhibition of CETP activity, the invention also provides for the use of the compound to prevent or treat atherosclerosis or hyperlipidemia.Type: ApplicationFiled: March 21, 2012Publication date: February 28, 2013Applicant: JAPAN TOBACCO INC.Inventors: Hisashi Shinkai, Kimiya Maeda, Hiroshi Okamoto
-
Patent number: 8343994Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.Type: GrantFiled: October 9, 2009Date of Patent: January 1, 2013Assignee: Japan Tobacco Inc.Inventors: Takahisa Motomura, Hironobu Nagamori, Koichi Suzawa, Hirotsugu Ito, Toru Morita, Satoru Kobayashi, Hisashi Shinkai
-
Patent number: 8232401Abstract: An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.Type: GrantFiled: June 5, 2006Date of Patent: July 31, 2012Assignee: Japan Tobacco Inc.Inventors: Motohide Satoh, Hiroshi Kawakami, Yoshiharu Itoh, Hisashi Shinkai, Takahisa Motomura, Hisateru Aramaki, Yuji Matsuzaki, Wataru Watanabe, Shuichi Wamaki
-
Patent number: 7960408Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR?. In particular, the compounds of the invention modulate the function of PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.Type: GrantFiled: February 17, 2009Date of Patent: June 14, 2011Assignee: Amgen Inc.Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
-
Patent number: 7872004Abstract: The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an anti-HIV agent, or as an agent for the prophylaxis or treatment of AIDS. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.Type: GrantFiled: June 22, 2007Date of Patent: January 18, 2011Assignee: Japan Tobacco Inc.Inventors: Motohide Satoh, Hisateru Aramaki, Masaki Yamashita, Masafumi Inoue, Hiroshi Kawakami, Hisashi Shinkai, Hiroshi Nakamura, Yuji Matsuzaki, Shuichi Wamaki
-
Patent number: 7807701Abstract: A dibenzylamine compound represented by the formula (1) wherein R1 and R2 are each a C1-6 allyl group optionally substituted by halogen atoms and the like; R3, R4 and R5 are each a hydrogen atom, a halogen atom and the like, or R3 and R4 may form, together with carbon atoms bonded thereto, a homocyclic or heterocyclic ring optionally having substituent(s); A is —N(R7)(R8) and the like; ring B is an aryl group or a heterocyclic residue; R6 is a hydrogen atom, a halogen atom, a nitro group, a C1-6 allyl group and the like; n is an integer of 1 to 3, a prodrug thereof and a pharmaceutically acceptable salt thereof show selective and potent CETP inhibitory activity, and therefore, they can be provided as therapeutic or prophylactic agents for hyperlipidemia or arteriosclerosis and the like.Type: GrantFiled: November 13, 2007Date of Patent: October 5, 2010Assignee: Japan Tobacco Inc.Inventors: Kimiya Maeda, Hironobu Nagamori, Hiroshi Nakamura, Hisashi Shinkai, Yasunori Suzuki, Daisuke Takahashi, Toshio Taniguchi
-
Publication number: 20100240634Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.Type: ApplicationFiled: October 9, 2009Publication date: September 23, 2010Applicant: JAPAN TOBACCO INC.Inventors: Takahisa Motomura, Hironobu Nagamori, Koichi Suzawa, Hirotsugu Ito, Toru Morita, Satoru Kobayashi, Hisashi Shinkai
-
Publication number: 20100197736Abstract: The present invention provides a CETP activity inhibitor comprising as an active ingredient a compound represented by the formula (I): wherein R represents a straight chain or branched alkyl group; a straight chain or branched alkenyl group; a lower haloalkyl group; a substituted or unsubstituted cycloalkyl group; a substituted or unsubstituted cycloalkenyl group; a substituted or unsubstituted cycloalkylalkyl group; a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group, X1, X2, X3, and X4 may be the same or different and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower haloalkyl group; a lower alkoxy group; a cyano group; a nitro group; an acyl group; or an aryl group, Y represents —CO— or —SO2—, and Z represents a hydrogen atom or a mercapto-protecting group, or a prodrug compound, a pharmaceutically acceptable salt, or hydrate or solvate thereof.Type: ApplicationFiled: July 13, 2009Publication date: August 5, 2010Applicant: Japan Tobacco Inc.Inventors: Hisashi SHINKAI, Kimiya Maeda, Hiroshi Okamoto
-
Patent number: 7745459Abstract: A pharmaceutical agent having an anti-HIV action, particularly, a pharmaceutical agent having an integrase inhibitory action, is provided. The present invention relates to a quinolizinone compound represented by the following formula [I] wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing same as an active ingredient. The compound of the present invention has an HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compounds can become a more effective anti-HIV agent. Since the compound has a high inhibitory activity specific for integrases, the compound can provide a safe pharmaceutical agent for human with a fewer side effects.Type: GrantFiled: September 20, 2005Date of Patent: June 29, 2010Assignee: Japan Tobacco Inc.Inventors: Motohide Satoh, Hisateru Aramaki, Hiroshi Nakamura, Masafumi Inoue, Hiroshi Kawakami, Hisashi Shinkai, Yuji Matsuzaki, Kazunobu Yamataka
-
Patent number: 7601841Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR?. In particular, the compounds of the invention modulate the function of PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.Type: GrantFiled: November 20, 2003Date of Patent: October 13, 2009Assignees: Amgen Inc., Japan Tobacco, Inc.Inventors: Lawrence R. McGee, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai
-
Publication number: 20090221635Abstract: Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by PPAR?. In particular, the compounds of the invention modulate the function of PPAR?. The subject methods are particularly useful in the treatment and/or prevention of diabetes, obesity, hypercholesterolemia, rheumatoid arthritis and atherosclerosis.Type: ApplicationFiled: February 17, 2009Publication date: September 3, 2009Applicants: Amgen Inc., Japan Tobacco. Inc.Inventors: Lawrence R. McGee, Jonathan B. Houze, Steven M. Rubenstein, Atsushi Hagiwara, Noboru Furukawa, Hisashi Shinkai